Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: A potential future tool for dual vaccination against dengue virus and HIV

BMC Microbiology

Volumn 1, Issue , 2001, Pages 1-9

  Pang, Xiaowu ^a   Zhang, Mingjie ^a   Dayton, Andrew I ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN; VIRUS RNA; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; GENE CONSTRUCT; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; REPLICON; TISSUE CULTURE; VIRUS GENE; ACTIVE IMMUNIZATION; DENGUE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; METHODOLOGY; VACCINATION;

ANIMALIA; DENGUE VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

DENGUE; DENGUE VIRUS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNOTHERAPY, ACTIVE; RECOMBINANT PROTEINS; REPLICON; RNA, VIRAL; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 19044388219     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-1-28     Document Type: Article

References (45)

1. Nathanson N, Mathieson BJ: Biological Considerations in the Development of a Human Immunodeficiency Virus Vaccine. Journal of Infectious Diseases 2000, 182:579-589
2. Cho MW: Assessment of HIV Vaccine Development: Past, Present, and Future. Advances in Pharmacology 2000, 49:263-314
3. Clerici M, Giorgi JV, Chou CC, et al: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019
4. Kaul R, Kimani J, Dong T, et al: Late seroconversion in HIV "resistant" Nairobi prostitutes is associated with a preceding decrease in HIV exposure. [abstract 489]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). San Francisco: Foundation for Retrovirology and Human Health, 2000168
5. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D, Bronson R, Greene MF, McClure HM, Martin LN, Ruprecht RM: Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat. Med 1999, 5:194-203
6. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267:1820-1825
7. Bogers WM, Niphuis H, ten Haaft P, Laman JD, Koornstra W, Heeney JL: Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: Consequences of challenge. AIDS 1995, 9:F13-F18
8. Greenough TC, Sullivan JL, Desrosiers RC: Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N. Engl. J. Med, 1999, 340:236-237
9. Berkhout B, Verhoef K, van Wamel JL, Back NK: Genetic instability of live, attenuated human immunodeficiency virus type 1 vaccine strains. J. Virol 1999, 73:1138-1145
10. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK: An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants. Cell 2001, 106:539-549
11. Khromykn AA, Westaway ED: Sub-genomic replicons of the flavivirus Kunjin: construction and applications. J. Virol 1997, 71(2):1497-1505
12. Pang X, Zhang M, Dayton AI: Development of dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiology 20011-18
13. Reitter J, Means R, Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nat Med 1998, 4:679-684
14. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93:681-684
15. LaCasse RA, Follis KE, Trahey M, et al: Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999, 283:357-362
16. Cooney EL, Collier AC, Greenberg PD, Coombs RW, Zarling J, Arditti DE, Hoffman MC, Hu SL, Corey L: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337(8741):567-572
17. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A 1993, 90(5):1882-1886
18. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, Gorse GJ, Midthun K, Keefer MC, Roberts NJ Jr, et al: Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992, 166(2):244-52
19. McElrath MJ, Corey L, Berger D, Hoffman MC, Klucking S, Dragavon J, Peterson E, Greenberg PD: Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994, 169(1):41-47
20. Monath TP: Dengue: the risk to developed and developing countries. Proc Natl Acad Sci USA 1994, 91:2395-2400
21. Morens DM: Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clinical Infectious Diseases 1994, 19:500-512
22. Halstead SB: Pathogenesis of dengue: Challenges to molecular biology. Science 1988, 239:476-481
23. Chambers TJ, Chang HS, Galler R, Rice CM: Flavivirus Genome Organization, Expression and Replication. Ann Rev Microbiol 1990, 44:649-6888
24. Rice CM: Flaviviridae: the virus and their replication. In: Fields Virology 3rd ed. Philadelphia, Pa. Lippincott-Raven Publishers, 1996931-996
25. Thomas CJ, Hahn CS, Galler R, Rice CM: Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990, 44:649-88
26. Heinz FX: Epitope mapping of flavivirus glycoproteins. Adv Virus Res 1986, 31:103-168
27. Bhamarapravati N, Sutee Y: Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18 Suppl 2:44-47
28. Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn I, Innis BL, Saluzzo JF, Hoke CH Jr: Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19(23-24):3179-3188
29. Schlesinger JJ, Brandriss MW, Walsh EE: Immunization with the dengue 2 virus nonstructural glycoprotein NS1. J. Gen. Virol 1987, 68:853-857
30. Falgout B, Bray M, Schlesinger JJ, Lai C-J: Immunization of Mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol 1990, 64(9):4356-4363
31. Henchal EA, Henchal LS, Schlesinger JJ: Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol 1988, 69 (Pt 8):2101-2107
32. Brinton MA, Kurane I, Mathew A, Zeng L, Shi PY, Rothman A, Ennis FA: Immune mediated and inherited defenses against flaviviruses. Clin Diagn Virol 1998, 10(2-3):129-39
33. Dittmer U, Brooks DM, Hasenkrug KJ: Protection against establishment of retro viral persistence by vaccination with a live attenuated virus. J Virol 1999, 73:3753-3757
34. Heeney J, Akerblom L, Barnett S, et al: HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 1999, 66:189-95
35. Hirsch V, Fuerst T, Sutter G, et al: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996, 70:3741-3752
36. Quesada-Rolander M, Makitalo B, Thorstensson R, et al: Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retroviruses 1996, 12:993-999
37. Letvin NL, Montefiori D, Yasutami Y, et al: Potent, protective anti-HIV immune response generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997, 94:9378-383
38. Miller CJ, McChesney MB, Lu X, et al: Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 1997, 71:1911-1921
39. Shibata R, Siemon C, Czajak SC, et al: Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus. J Virol 1997, 71:8141-8148
40. Gundlach B, Reiprich S, Sopper S, et al: Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol 1998, 72:7846-7251
41. Girard M, Habel A, Chanel C: New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview. C R Acad Sci III 1999, 322(11):959-966
42. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L: The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75(12):5526-5540
43. Polo S, Ketner G, Levis R, Falgout B: Infectious RNA Transcripts from full-length dengue virus type 2 cDNA clones made in Yeast. J Virol 1997, 71(7):5366-5374
44. Pur B, Polo S, Hayes CG, Falgout B: Construction of a full length infection clone for dengue-1 virus western pacific 74 strain. Virus Genes 2000, 20(1):57-63
45. Spencer F, Ketner G, Connelly C, Hieter P: Targeted recombination-based cloning and manipulation of large DNA segments in yeast. Methods Companion Methods Enzymol 1993, 5:161-175